Mertenil

Mertenil – the synthetic medicine applied as addition to a dietotherapy to decrease in cholesterol at treatment of a hypercholesterolemia and the combined dislipidemichesky states.

Pharmacological action of Mertenil

Active component of Mertenil (розувастатин calcium) leads to decrease in level both the general cholesterol, and cholesterol of lipoproteins of low density. Being the selection and competitive inhibitor of GMG-KOA-reduktazy (enzyme – the predecessor of cholesterol), розувастатин influences a liver where there is a synthesis of cholesterol and a catabolism of lipoproteins of low density.

The effect of Mertenil's use is observed a week later since the beginning of drug intake, and therapy reaches the maximum in a month of use.

Form of release of Mertenil

Mertenil release in the form of the biconvex round tablets with a text of "C33" containing 5 mg, 10 mg, 20 mg and 40 mg of active component (a rozuvastatin of calcium).

On 10 tablets in strip planimetric packagings.

Mertenil's analogs

Medicines belong to Mertenil's analogs: Akorta, Krestor, Rozulip, Tevastor, Rozuvastatin, Roksera and Rozukard. Mertenil's analogs on the mechanism of action are tablets Avestatin, Lipona, Zorstat, Tulip, Liprimar, Anvistat, Simlo, Lovastatin, Simvastol, Leskol, Simplakor, Atomaks, Zokor, Torvakard, Zovatin, Aktalipid, Kardiostatin, Lipoford, Vazator, Simvakard, Simvastatin and Holvasim.

Indications to Mertenil's use

Mertenil according to the instruction appoint as addition to a dietotherapy at treatment:

• Hypercholesterolemia and the combined dislipidemichesky states in cases when non-drug methods are insufficiently effective (for example, decrease in body weight, physical exercises);
• Gipertriglitseridemiya of the fourth type across Fredrikson;
• Family homozygous hypercholesterolemia.

Besides, Mertenil accept for delay of rates of progressing of atherosclerosis and as primary prevention of such cardiovascular complications as a stroke, a heart attack and arterial revascularization in the absence of clinical signs of coronary heart disease at elderly people (men of 50 years and women of 60 years).

Contraindications

Mertenil it is contraindicated to apply:

• To pregnant women and the feeding women, and also women of childbearing age who do not apply well-tried remedies of contraception;
• Against the background of predisposition to development of miotoksichesky complications;
• At a myopathy;
• Along with cyclosporine and fibrata;
• Against the background of a liver failure;
• Against the background of hypersensitivity to components (active or auxiliary) a medicine, and also at a lactose intolerance and deficit of lactase, or glyukozo-galaktozny malabsorption;
• At the expressed renal failures;
• In pediatrics up to 18 years.

Also according to the instruction, Mertenil in tablets of 40 mg it is contraindicated to accept against the background of:

• Hypothyroidism;
• The diseases of a liver proceeding in an active phase;
• Excessive alcohol intake;
• Personal or family anamnesis of muscular diseases.

People of Asian race also should not take a pill of this dosage.

With care according to the instruction Mertenil appoint:

• Against the background of heavy disturbances of metabolic, endocrine or electrolytic character;
• Against the background of risk of development of a myopathy;
• At uncontrollable epilepsy;
• Against the background of liver diseases in the anamnesis;
• At injuries;
• To people 65 years are more senior;
• Against the background of arterial hypotension;
• Against the background of sepsis;
• At any extensive surgical interventions.

Mertenil route of administration

Mertenil according to the instruction it is possible to accept at any time, however during treatment it is necessary to keep to the diet registered by the doctor including products with the low content of cholesterol.

Mertenil's doses select individually depending on the purpose of the carried-out therapy. The initial dosage usually does not exceed 5-10 mg once a day. It is recommended to carry out its correction not earlier, than in a month from the moment of an initiation of treatment.

Mertenil's use in a dosage of 40 mg is possible only under careful observation of the doctor as drug intake against the background of the accompanying diseases of kidneys can provoke development of a proteinuria (preferential canalicular origin).

Correction of a daily dose, as a rule, is not required to elderly people. For people of an Asian origin, and also against the background of predisposition to a myopathy the initial dose of Mertenil should not be more than 5 mg, and use of a medicine in a dose of 40 mg is contraindicated.

Medicinal interaction

Joint reception of Mertenil with the means reducing the level of lipids (for example, with gemfibrozily) leads to increase in concentration of a rozuvastatin in blood.

Fenofibrat, gemfibrozit and niacin at simultaneous use with Mertenil increase risk of development of a myopathy therefore similar combinations of medicines are not recommended. Also it is not necessary to appoint at the same time Mertenil with inhibitors protease against the background of HIV.

Antacids in suspension (with the content of magnesium of hydroxide and aluminum) and erythromycin, promote decrease in concentration of active component of Mertenil in a blood plasma therefore it is necessary to observe an interval between reception of these medicines not less than two hours.

Side effects of Mertenil

As a rule, during Mertenil's reception, according to reviews, there can be short-term and moderately expressed side effects. At Mertenil's use in tablets of 5-20 mg development of a diabetes mellitus 2 types, nausea, an asthenic syndrome, dizziness, an abdominal pain, a headache, a lock and a mialgiya is most often observed. Slightly less often during the carried-out therapy by Mertenil, according to reviews, rash, hypersensitivity reactions, a skin itch, pancreatitis, a myopathy, a small tortoiseshell and рабдомиолиз are observed.

Frequency and expressiveness of disturbances from a liver and kidneys has dozozavisimy character. According to reviews, Mertenil at daily reception in a dose of 40 mg can lead to development:

• Mialgiya;
• Proteinurias (most often – a canalicular origin);
• Increases in concentration of glucose and bilirubin;
• Myopathies;
• Disturbances of indicators of function of a thyroid gland.

Extremely seldom against the background of Mertenil's use according to the instruction are observed:

• Arthralgia;
• Peripheral hypostases;
• Jaundice;
• Diarrhea;
• Hepatitis;
• Hamaturia;
• Memory loss;
• Polyneuropathy;
• Asthma;
• Cough.

In case of muscular weakness or unexpected sharp muscle pains which are accompanied by an indisposition and fever it is necessary to see a doctor at once and to cancel Mertenil's use or to reconsider the accepted medicine doses.

Storage conditions

Mertenil is among hypolipidemic medicines of a prescription issue with a period of validity to 24 months at observance of standard storage conditions (at a temperature up to 30 degrees Celsius).